New Delhi : Drug major Lupin is looking to strengthen its branded and specialty business in the US by launching new products, brand acquisitions and even buyout of other specialty companies which compliment its therapy focus. “The company is committed to strengthening its branded and specialty portfolio by leveraging, developing and launching products from its own pipeline (including Gavis) and through making strategic brand acquisitions or acquiring other specialty companies which compliment our therapy focus,” Lupin CFO Ramesh Swaminathan told PTI.
The company focuses on various therapeutic areas like paediatric, women’s health, inhalation, derma and ophthalmology for that matter, he added.
“The Methergine launch is definitely going to have a positive impact on our US revenues…our specialty and brands business is sure to pick up traction as we add new products to our brands portfolio which will contribute to firming up our profitability. The Methergine launch is one such instance,” he added. The US is Lupin’s largest market and contributed 45% to its revenue during 2014-15.
